Juliette Berangere Audet is Chief Business Officer at NewAmsterdam Pharma Co N.V. (NAMS). They have made 1 open-market trade across 1 company since 2024, most recently 2025-01-07.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $17K since 2024, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NAMS | 15,104 | $320K |
Shares reported on the most recent Form 4, priced at the 2025-01-07 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NAMS | BUY | 2024-09-26 | 2024-09-30 | $15.70 | $17K | +12.1% | +14.5% | +62.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.